Similar Articles |
|
The Motley Fool June 23, 2005 Rich Smith |
Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal. |
The Motley Fool June 23, 2005 Stephen D. Simpson |
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. |
The Motley Fool June 23, 2005 Stephen D. Simpson |
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? |
BusinessWeek July 25, 2005 Gene G. Marcial |
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion. |
The Motley Fool August 26, 2005 Stephen D. Simpson |
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. |
The Motley Fool December 21, 2006 Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |
The Motley Fool December 21, 2006 Ryan Fuhrmann |
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. |
The Motley Fool August 22, 2005 Stephen D. Simpson |
Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares. |
The Motley Fool January 31, 2005 Stephen D. Simpson |
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. |
The Motley Fool February 21, 2006 Rick Aristotle Munarriz |
Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes. |
The Motley Fool January 25, 2005 Stephen D. Simpson |
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. |
The Motley Fool December 21, 2006 Ryan Fuhrmann |
Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better. |
The Motley Fool September 18, 2007 Brian Orelli |
New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug. |
The Motley Fool July 8, 2010 Brian Orelli |
Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy. |
The Motley Fool December 21, 2006 Brian Lawler |
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. |
The Motley Fool September 7, 2007 Billy Fisher |
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. |
The Motley Fool October 23, 2007 Brian Orelli |
Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter. |
The Motley Fool April 17, 2007 Brian Lawler |
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. |
Chemistry World March 13, 2007 |
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. |
The Motley Fool October 23, 2006 Brian Lawler |
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. |
The Motley Fool January 31, 2007 Brian Lawler |
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. |
The Motley Fool October 4, 2004 Mathew Emmert |
Got Merck? The pharmaceutical's investors can't seem to catch a break. |
The Motley Fool May 21, 2008 Brian Orelli |
OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion? |
The Motley Fool November 25, 2011 Dan Caplinger |
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. |
The Motley Fool February 23, 2005 Stephen D. Simpson |
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. |
The Motley Fool October 24, 2005 Stephen D. Simpson |
Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors. |
The Motley Fool November 15, 2004 Mathew Emmert |
Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon. |
The Motley Fool January 25, 2006 Tim Hanson |
Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head. |
The Motley Fool February 22, 2005 Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
The Motley Fool July 24, 2006 Stephen D. Simpson |
Wait for a Bad Day at Merck Merck has value as a going concern, but investors should wait for some bad news to make the stock cheaper. |
BusinessWeek September 5, 2005 Amy Barrett |
The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come |
The Motley Fool January 27, 2004 Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool August 2, 2007 Brian Orelli |
98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news. |
The Motley Fool February 24, 2011 Jordan DiPietro |
Should You Retire With Merck? Is Merck a good choice for a retirement portfolio? |
The Motley Fool November 29, 2010 Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
The Motley Fool May 30, 2008 Brian Orelli |
For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly? |
Bio-IT World December 15, 2004 Kevin Davies |
Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first. |
The Motley Fool September 1, 2009 Brian Orelli |
Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company. |
The Motley Fool July 18, 2008 Brian Orelli |
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. |
The Motley Fool March 18, 2009 Brian Orelli |
Merck Pummels Pfizer One of these acquisitions is not like the other. |
The Motley Fool September 11, 2008 Brian Orelli |
Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in. |
The Motley Fool April 11, 2007 Billy Fisher |
A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders. |
The Motley Fool October 11, 2010 Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool October 21, 2004 Brian Gorman |
Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight. |
BusinessWeek December 5, 2005 Michael Orey |
Presto: A New Vioxx Liability Estimate! Why analysts' reports shift wildly with every twist in litigation against Merck. |
The Motley Fool November 25, 2009 Brian Orelli |
A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back. |
The Motley Fool September 30, 2004 W. D. Crotty |
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. |
The Motley Fool December 13, 2005 Rich Duprey |
Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors. |
The Motley Fool May 12, 2010 Brian Orelli |
Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong. |
The Motley Fool August 30, 2010 Brian Orelli |
It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface? |